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The Haematological Malignancy Research Network (HMRN): a
new information strategy for population based epidemiology
and health service research
Background
Haematological malignancies are common, being the fourth
most frequently diagnosed cancer in both males and females in
the economically developed regions of the world (Ferlay et al,
2004; Jemal et al, 2008; Westlake, 2008). There are over 60
recognized disease subtypes, which differ widely in clinical
presentation, treatment requirements and prognosis (World
Health Organization [WHO], 2008). Key to the delivery and
management of high-quality cancer services for this diverse
patient group is a successful information strategy, with access
to reliable, detailed and relevant data on disease frequency and
outcome (Jensen et al, 1991; National Institute for Clinical
Excellence [NICE], 2003; Department of Health, 2007).
Equally, it is critically important to accurately describe and
understand underlying disease patterns in order to originate
and test hypotheses about pathogenesis (Boyle & Levin, 2008).
Globally, cancer information gathering and dissemination is
sustained by national programmes, such as the Surveillance,
Epidemiology and End Results (SEER) Program in the United
States (US) (http://www.seer.cancer.gov) and the National
Cancer Research Institute (NCRI) in the United Kingdom
(UK) (http://www.ncri.org.uk), as well as international orga-
nizations, such as the WHO International Agency for Research
on Cancer (http://www.iarc). The success of these cancer
information systems should be judged not only by the utility of
their data, but also by the conﬁdence that the end-users have in
the accuracy and analytical methods employed. Whilst meeting
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Summary
The Haematological Malignancy Research Network (HMRN) was established
in 2004 to provide robust generalizable data to inform clinical practice and
research. It comprises an ongoing population-based cohort of patients newly
diagnosed by a single integrated haematopathology laboratory in two
adjacent UK Cancer Networks (population 3Æ6 million). With an emphasis
on primary-source data, prognostic factors, sequential treatment/response
history, and socio-demographic details are recorded to clinical trial
standards. Data on 8131 patients diagnosed over the 4 years 2004–08 are
examined here using the latest World Health Organization classiﬁcation.
HMRN captures all diagnoses (adult and paediatric) and the diagnostic age
ranged from 4 weeks to 99 years (median 70Æ4 years). In line with published
estimates, ﬁrst-line clinical trial entry varied widely by disease subtype and
age, falling from 59Æ5% in those aged <15 years to 1Æ9% in those aged over
75 years – underscoring the need for contextual population-based treatment
and response data of the type collected by HMRN. The critical importance of
incorporating molecular and prognostic markers into comparative survival
analyses is illustrated with reference to diffuse-large B-cell lymphoma, acute
myeloid leukaemia and myeloma. With respect to aetiology, several
descriptive factors are highlighted and discussed, including the unexplained
male predominance evident for most subtypes across all ages.
Keywords: diagnostic haematology, epidemiology, leukaemia, lymphoma,
myeloma.
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particularly problematic for haematological malignancies
where information gathering and dissemination has long been
acknowledged as a major problem. These concerns were
recently summarized by EUROCARE 4 in their statement that
‘the evolving classiﬁcation and poor standardization of data
collected on hematological malignancies vitiate the compari-
sons of disease incidence and survival over time and across
regions’(Sant et al, 2009).
A primary requirement of any successful cancer information
strategy is the accurate estimation of disease burden. For
haematological malignancies, two major issues need to be
addressed in order to begin to produce useful data – complete
unbiased ascertainment and accurate capture of detailed
diagnostic data. Traditionally, descriptive information is
reported in the four broad categories shown in Fig 1, which
summarizes data from the UK. This practice stems from the
gradual recognition of clinical entities in the latter half of the
nineteenth century, and originated long before there were any
effective treatments or real understanding of the relationship
between haematological malignancy, the normal bone marrow
and immune system, and before anything was known about
the cellular and genetic basis of malignant transformation.
However, the continued application of such broad categori-
zations severely limits the use of cancer registration data in
epidemiological studies, and the high level of clinical diversity
among the subtypes contained within each of the traditional
groupings means that data presented in this way are of little
value for health service planning and making valid compar-
isons of outcome (NICE, 2003; Sant et al, 2009).
Critically for descriptive epidemiology, the classiﬁcation of
haematological malignancy has changed markedly over recent
decades, and will continue to do so as innovative diagnostic
methods and techniques are developed (WHO, 2001, 2008).
Fig 1. Cancer registrations United Kingdom, 2005.
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classiﬁcation that deﬁned disease entities in terms of immu-
nophenotype, genetic abnormalities and clinical features.
However, although this classiﬁcation was adopted into clinical
practice almost uniformly around the world, it did not have an
immediate effect on cancer registration practice, where lack of
consistency in the depth and detail of pathological diagnosis
means that population-based data continues to be reported in
broad disease categories (Ferlay et al, 2004; Verdecchia et al,
2007; Jemal et al, 2008; Westlake, 2008; National Cancer
Intelligence Network, 2009a; Rachet et al, 2009). This is largely
a reﬂection of the fact that unlike many other cancers,
haematological neoplasms are diagnosed using multiple
parameters including a combination of histology, cytology,
immunophenotyping, cytogenetics, imaging and clinical data.
This range and depth of data is difﬁcult for cancer registries to
access systematically, forming a barrier both to the complete
ascertainment and to the collection of diagnostic data at the
level of detail required to implement the latest WHO
classiﬁcation (WHO, 2001, 2008). Furthermore, in practice,
even within some of the best deﬁned WHO categories there is a
need to qualify the ﬁnal diagnosis even further using additional
clinical and biological prognostic factors before valid outcome
comparisons can be made (The International Non-Hodgkin’s
Lymphoma Prognostic Factors Project, 1993; Hasenclever &
Diehl, 1998; Vasconcelos et al, 2003; Weltermann et al, 2004;
Buske et al, 2006; Sehn et al, 2007; Dicker et al, 2009).
The diagnostic complexity of haematological malignancies is
mirrored by the wide diversity of treatment pathways. This
diversity includes not only the intensity of treatment, but also
its purpose and its duration. Whilst most cancer treatment can
be categorized as potentially curative or palliative, there are
increasing numbers of patients being diagnosed with more
indolent forms of haematological malignancy whose life
expectancy has been improved through increasingly effective
therapy delivered continuously or episodically over a pro-
tracted period of time (National Institute for Clinical Excel-
lence, 2003; O’Brien et al, 2003; Weber et al, 2007). Indeed, for
many conditions, such as chronic myeloid leukaemia (CML),
the prevalence of patients on active treatment is now many
times greater than the annual incidence; and these treatment
developments are having a major impact on the health
economy (Department of Health, 2007). Longitudinal data of
the type required to inform these changes are not routinely
collected, but are clearly of critical importance for planning
future haemato-oncology services, as well as for modelling the
impact of new treatment approaches.
In response to the challenges outlined above, the Haema-
tological Malignancy Research Network (HMRN) was estab-
lished in the UK in 2004 (http://www.hmrn.org). HMRN was
devised with the overarching aim of overcoming existing
limitations and producing high quality functional data
through the development of an innovative population-based
registry. This unique venture combines the expertise of a single
integrated haematopathology laboratory, an active clinical
network, and data collection/analysis conducted by a specialist
epidemiology unit. This paper describes the infrastructure of
HMRN and discusses the use of the data, demonstrating its
potential to support epidemiological research as well as health
service planning and management.
Methods
In the UK, cancer care is co-ordinated through a series of 37
area-based Cancer Networks, each covering a population
between 700 000 and 3 million people. Cancer Networks are
responsible for bringing together health service commissioners
and providers, the voluntary sector and local authorities to
deliver high quality care within the UK National Health Service
(NHS). HMRN collects detailed information about all haema-
tological malignancies diagnosed in two adjacent UK Cancer
Networks; these are the Yorkshire Cancer Network and the
Humber & Yorkshire Coast Cancer Network (total population
3Æ6 million).
Within the HMRN region, patient care is provided by a
uniﬁed clinical network operating across 14 hospitals orga-
nized within ﬁve adult multi-disciplinary teams (MDTs) and a
network-wide paediatric oncology service. As a matter of
policy, all haematological malignancy diagnoses within the
region (whether originating from the NHS or private sources
and irrespective of assumed prognosis and treatment intent)
are made at a single specialist haematopathology laboratory –
the Haematological Malignancy Diagnostic Service (http://
www.HMDS.org) – and it is from here that all HMRN patients
are ascertained. HMDS, which was cited in the 2007 UK
Department of Health Cancer Reform Strategy as ‘the model
for delivery of complex diagnostic services’(Department of
Health, 2007), provides a fully integrated diagnostic pathway
in a single department, bringing together the relevant
technology and expertise (including histology, cytology,
immunophenotyping and molecular cytogenetics) required
for the diagnosis and on-going monitoring of all haematolog-
ical malignancies. A sophisticated custom-designed web data-
base is used to handle clinical diagnoses, specimen tracking
and reporting; all diagnoses, including disease transformations
and progressions, are automatically coded to International
Classiﬁcation of Diseases for Oncology, 3rd Edition (ICD-O-3)
(WHO, 2000).
Network clinical teams work to common guidelines cover-
ing investigation, treatment and follow-up. Following diagno-
sis a core clinical dataset is extracted for all patients from
medical records at each of the 14 HMRN hospitals. Whilst the
vast majority of patients are treated within haematology,
records are traced across the various other disciplines and
hospitals involved in patient care in order to reﬂect the totality
of the pathway. The information collected includes demo-
graphic details, prognostic factors including imaging, and a full
sequential treatment history with response and outcome
recorded for all episodes. These data are acquired by a process
of active collection by expert HMRN dedicated research staff,
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with strict and continuous cross-validation within a transpar-
ent peer review process. A critically important feature of data
acquisition is the emphasis on primary source information;
and whilst details of disease stage at diagnosis are recorded if
documented in the medical records, primary data from
radiology reports, blood tests, clinical examination, and
clinician summaries are also recorded, enabling embedded
algorithms to automatically generate stage and prognostic
scores. All details are abstracted onto structured forms (each
malignancy having its own specially adapted version) and
entered onto the web-based system, which integrates HMRN
and HMDS data. Full details of the HMRN and copies of data
abstraction forms are shown on our website (http://
www.hmrn.org).
HMRN has full ethical approval and Section 60 exemption
(now Section 251) to collect data for audit and research on
haematological malignancy patients diagnosed within the
region. For the purposes of the present analysis, population
data were obtained for the HMRN region and for the UK as a
whole from the 2001 census (Ofﬁce for National Statistics,
2001). Incidence rates and corresponding 95% conﬁdence
intervals (CIs) were estimated using Poisson regression and
survival curves by the Kaplan–Meier method. All analyses were
conducted using the Stata 10 statistical software (Stata-
Corp LP, College Station, TX, USA).
Results
Descriptive ﬁndings are presented here for 8131 patients newly
diagnosed with a haematological neoplasm between 1 Sep-
tember 2004 and 31 August 2008 in the HMRN region. Of
these, 224 (2Æ8%) patients had a second haematological
neoplasm diagnosed during the 4-year period either because
of disease progression or transformation, or because of a
concurrent diagnosis with a different cell lineage, yielding 8355
diagnoses in total. These 8355 diagnoses are distributed
according to the WHO 2001 classiﬁcation (WHO, 2001) in
Table I. Twenty-three main groupings are shown in bold, and
contributory subtypes with ﬁve or more diagnoses are also
listed. In addition to frequency, information on sex (% male),
age at diagnosis (median) and ﬁrst line clinical trial recruit-
ment (% of total) are also presented.
Whist a haematological malignancy can occur at any age, as
with most other cancers, the likelihood of diagnosis increased
markedly with increasing age (Fig 2). The median age at
diagnosis within HMRN over the 4 years 2004–08 was
70Æ4 years for all haematological neoplasms combined, with a
range of 4 weeks to 99 years. Age-speciﬁc male rates were
generally higher than female rates (lines in Fig 2), the
divergence between the two becoming progressively more
marked over the age of 50 years. There was clearly a
pronounced male excess across the majority of myeloid and
lymphoid subtypes, but despite this, more women than men
were diagnosed over the age of 80 years (bars in Fig 2). This
apparent discrepancy arose because more women than men
survive to reach old age, as can be seen from Fig 3 which shows
the age and sex structure of HMRN’s population (bars) as well
as that of the UK as a whole (lines).
With a combined population of 3Æ6 million it is, perhaps,
not surprising that HMRN’s regional structure mirrored that
of the UK as a whole in terms of age and sex (Fig 3). Average
annual incidence rates for the 23 main groups and expected
annual frequencies for the UK as a whole, estimated by
applying HMRN sex- and age- (5-year age strata) speciﬁc rates
to equivalent UK sex- and age-speciﬁc population strata, are
presented in Table II. A direct comparison with published
ﬁgures could not be made as national cancer registrations are
not coded to ICD-O-3, and not all of the categories shown in
Table II were uniformly compiled (myeloproliferative neo-
plasms and myelodysplastic syndromes, for example). This is
one of the reasons why, for both males and females, the overall
estimated levels based on HMRN rates are almost 50% higher
than the 2005 UK cancer registration frequencies presented in
Fig 1. More detailed downloadable user-deﬁned breakdowns
by subtype, age and sex can be obtained from our website
(http://www.hmrn.org).
The sex-speciﬁc incidence rate ratios (male rate/female rate)
together with their standard errors are shown separately for
myeloid and lymphoid subtypes with 10 or more diagnoses in
Fig 4, which is ordered according to the magnitude of the rate
ratio. As might be expected, some related conditions had
similar sex rate ratios, that of monoclonal gammopathy of
undetermined signiﬁcance (MGUS) and myeloma, for exam-
ple, being identical (1Æ4; 95% CI, 1Æ2–1Æ6). Whereas for others,
such as chronic lymphocytic leukaemia (CLL, 1Æ7; 95% CI, 1Æ5–
2Æ0) and monoclonal B-cell lymphocytosis (MBL, 1Æ2; 95% CI,
1Æ0–1Æ5) there were differences. Variations were also evident
within some of the main diagnostic categories. For acute
myeloid leukaemia (AML), for example, the overall rate ratio
was 1Æ1, but this ranged from 0Æ7 for therapy-related AML to
1Æ9 for AML with core binding factor. Likewise T-cell
lymphomas, with an overall rate ratio of 1Æ4, ranged from
for 0Æ5 for angioimmunoblastic T-cell lymphoma to 2Æ1 for
anaplastic large cell lymphoma of T/null type.
Box and whisker summary age plots broadly arranged
according to the magnitude of the median ages given in the
third column of Table I are shown separately for myeloid and
lymphoid subtypes with 10 or more diagnoses in Fig 5. Among
myeloid neoplasms, AML spanned the entire age range.
However, this concealed distinct patterns associated with
genetically deﬁned subtypes. For example, the median age of
patients with 11q23 rearrangements was 17Æ9 years, demon-
strating that this largely paediatric malignancy nevertheless
occurs sporadically up to the age of 50 years. At the other end
of the age spectrum, therapy-related AML had a median age of
71 years and was not recorded in the present series of HMRN
patients before the age of 55 years. A strong relationship
between age and subtype was also evident among lymphoid
neoplasms, the median age at diagnosis ranging from
A. Smith et al
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Neoplasm (ICD–O3) Total
Males
(%)
Median age
at diagnosis
(years)
First Line
treatment trial
entry (%)
All diagnoses 8355 54Æ97 0 Æ47 Æ2
Chronic myeloid leukaemia (9875/3) 137 61Æ35 9 Æ11 1 Æ0
Myeloproliferative neoplasms 822 41Æ57 1 Æ40 Æ2
Chronic myeloproliferative neoplasm (9960/3) 750 40Æ17 1 Æ20 Æ3
Chronic myeloproliferative neoplasm with myeloﬁbrosis (9961/3) 55 61Æ87 3 Æ9–
Hypereosinophilic syndrome (9964/3) 9 44Æ45 5 Æ5–
Systemic mastocytosis (9741/3) 8 25Æ06 2 Æ5–
Chronic myelomonocytic leukaemia (9945/3) 76 63Æ27 5 Æ6–
Myelodysplastic syndromes 509 69Æ07 5 Æ94 Æ7
Refractory anaemia with ringed sideroblasts (9982/3) 96 62Æ57 7 Æ4–
Refractory anaemia with excess blasts (9983/3) 220 68Æ27 5 Æ19 Æ5
Refractory cytopenia with multilineage dysplasia (9985/3) 193 73Æ17 5 Æ9–
Acute myeloid leukaemia (AML) 570 52Æ16 8 Æ53 4 Æ4
AML not otherwise speciﬁed (NOS) (9861/3 9895/3) 462 52Æ67 1 Æ43 2 Æ3
AML with core binding factors (9871/3 9896/3) 28 64Æ34 2 Æ95 3 Æ6
AML – probable therapy-related (9920/3) 26 38Æ57 1 Æ07 Æ7
AML with MLL (11q23) rearrangement (9897/3) 10 30Æ01 7 Æ97 0 Æ0
APML t(15;17)(q22;q11–12) (9866/3) 44 52Æ33 8 Æ55 2 Æ3
Precursor B-lymphoblastic leukaemia (9836/3) 137 52Æ61 2 Æ86 8 Æ6
Monoclonal B-cell Lymphocytosis 385 53Æ07 1 Æ6–
Chronic lymphocytic leukaemia (9823/3) 835 62Æ07 1 Æ80 Æ6
Marginal zone lymphoma 390 54Æ47 1 Æ93 Æ1
Systemic marginal zone lymphoma (9699/3) 296 56Æ87 2 Æ24 Æ1
Extranodal marginal zone lymphoma (9699/3) 94 46Æ86 8 Æ9–
Hairy cell leukaemia (9940/3) 48 75Æ06 8 Æ0–
Monoclonal gammopathy of undetermined signiﬁcance (9765/1) 892 56Æ47 2 Æ2–
Plasma cell myeloma (9732/3) 876 57Æ07 2 Æ81 3 Æ7
Plasmacytoma (9731/3, 9734/3) 68 64Æ76 8 Æ81 3 Æ2
Follicular lymphoma (9690/3, 9698/3) 446 46Æ26 4 Æ13 Æ8
Mantle cell lymphoma (9673/3) 100 62Æ07 4 Æ38 Æ0
Diffuse large B-cell lymphoma (9680/3) 1098 52Æ67 0 Æ04 Æ5
Diffuse large B-cell lymphoma (9680/3) 1085 52Æ67 0 Æ24 Æ5
Mediastinal large B-cell lymphoma (9679/3) 13 53Æ83 1 Æ7–
Burkitt lymphoma (9687/3) 54 79Æ64 8 Æ27 Æ4
Lymphoproliferative disorders NOS (9823/3, 9591/3) 263 52Æ97 6 Æ8–
Precursor T-lymphoblastic leukaemia (9837/3) 43 65Æ11 7 Æ55 5 Æ8
T-cell leukaemia 50 48Æ07 5 Æ02 Æ0
T-cell or natural killer cell large granular lymphocytosis (9831/3) 40 52Æ57 2 Æ72 Æ5
T-cell prolymphocytic leukaemia (9834/3) 10 30Æ07 8 Æ3–
T-cell lymphoma 156 57Æ76 4 Æ30 Æ6
Peripheral T-cell lymphoma – common; unspeciﬁed (9702/3) 49 63Æ36 8 Æ6–
Mycosis fungoides (9700/3) 28 71Æ46 4 Æ7–
Primary cutaneous CD30 positive T-cell (9718/3) 23 43Æ55 2 Æ3–
Anaplastic large cell lymphoma of T/null type (9714/3) 18 66Æ75 5 Æ65 Æ6
Angioimmunoblastic T-cell lymphoma (9705/3) 16 31Æ37 4 Æ0–
Enteropathy-type T-cell lymphoma (9717/3) 10 50Æ06 2 Æ8–
Extranodal NK/T-cell lymphoma, nasal type (9719/3) 9 44Æ46 1 Æ6–
Lymphocyte predominant nodular Hodgkin lymphoma (9659/3) 40 72Æ54 3 Æ6–
Classical Hodgkin Lymphoma 360 51Æ14 2 Æ15 Æ8
Nodular sclerosis classical Hodgkin lymphoma (9663/3) 262 48Æ93 7 Æ05 Æ7
Mixed cellularity classical Hodgkin lymphoma (9652/3) 91 54Æ96 0 Æ05 Æ5
Lymphocyte-rich classical Hodgkin lymphoma (9651/3) 7 85Æ75 6 Æ61 4 Æ3
Descriptive Epidemiology of Haematological Malignancies
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78Æ3 years for T-cell prolymphocytic leukaemia (Fig 5B). As
well as contrasts, the similarity of the age distributions of
closely related conditions was striking. MBL and CLL, for
example, were adjacent in the plots – the median ages at
diagnosis were 71Æ6 and 71Æ8 years, respectively. Likewise,
MGUS and myeloma had median ages of 72Æ2 and 72Æ8 years,
respectively.
The importance of examining speciﬁc disease entities is
further illustrated with reference to AML in Fig 6A, which plots
survival for AML WHO ICD-O-3 categories with 25 or more
patients. In general, prognosis for adults diagnosed with AML
was recognized to be poor, but there was considerable
heterogeneity by subtype with almost three-quarters of those
diagnosed with acute promyelocytic leukaemia t(15;17)(q22;
q11–12) surviving beyond 4 years. In addition to age and
diagnostic category, additional prognostic markers also impact
on survival. This is illustrated further in Fig 6B, which
examines the survival of patients diagnosed with AML not
otherwise speciﬁed (NOS) according to the mutation status of
the tyrosine kinase receptor FLT3 – those with the mutation
had a signiﬁcantly poorer survival than those without it
(P =0 Æ006). In the case of B-cell malignancies, clinical indices
based on disease bulk and patient ﬁtness are a well-validated
method of predicting outcome. An example of these prognostic
indicators for B-cell lymphomas is illustrated in Fig 7, which
shows the components of the International Prognostic Index
(IPI) for diffuse large B-cell lymphoma, based on 1043 patients
over 18 years of age who had no prior B-cell disease. The
combinations of cellular and clinical prognostic factors, the
components of which vary according to disease subtype, are
essential for the accurate deﬁnition of any given patient
population.
The ﬁnal column of Table I gives the proportion of patients
entered into a clinical trial as their ﬁrst line treatment, which
for all haematological malignancies combined was only 7Æ2%,
ranging from 59Æ5% in those under 15 years through to 1Æ9%
in those aged 75 years or more. The highest trial entry was for
precursor B-lymphoblastic leukaemia, reﬂecting the well
recognized high levels of recruitment for this largely paediatric
cancer. For many other conditions, particularly those that
dominate the older age ranges, recruitment was very low, as
can be seen more clearly in Table III where ﬁrst line trial entry
proportions are distributed by age at diagnosis and diagnostic
category.
A key determinant of outcome and the health resource
invested is the treatment the patient received throughout the
entire course of their cancer pathway. With the treatment
pathways of haematological malignancies having the potential
to be both multifaceted and protracted, collecting and
presenting these data is particularly challenging. The ability
of our data to reveal this complexity is illustrated in Fig 8
which shows the pathways of two HMRN myeloma patients,
one in a trial and one not in a trial. Following diagnosis, both
patients were constantly monitored within the haematology
department, and had multiple treatment episodes directed
both at disease control and at symptom management. The ﬁrst
patient, whose disease followed an aggressive course, died
940 d (2Æ6 years) after diagnosis following intensive salvage
treatment with various modalities – radiotherapy as well as
multiple episodes of chemotherapy. The second patient,
however, followed a more indolent course but ultimately still
required multiple lines of treatment and is currently being
treated with lenalidomide 4 years after diagnosis.
Discussion
The Haematological Malignancy Research Network (HMRN)
was established as a resource to support multifaceted popu-
lation-based research and to provide ‘real-time’ information
for monitoring and improving patient care. To achieve these
aims it was necessary to design a system of data collection that
attained a level of detail and completeness that is beyond the
remit of conventional population-based cancer registries. The
success of this programme, as illustrated by the data presented
Fig 2. Age and sex distribution: Haematological Malignancy Research
Network (HMRN), 2004–2008.
Fig 3. Population age and sex structure of the Haematological
Malignancy Research Network (HMRN) region (bars) compared to the
UK as a whole (lines), 2001.
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analysis pathway that integrated the key diagnostic and clinical
components in a single platform managed by an interdisci-
plinary team with expertise in diagnostics, clinical haemato-
logy and epidemiology.
Epidemiological reports on haematological malignancy
often begin, and sometimes end, by stating that little is known
about the aetiology of the condition(s) under study. The use of
appropriate disease classiﬁcations is critical to the research
process; hitherto, however, many studies of haematological
malignancy have been hampered by the need to aggregate their
data into broad groupings, either because primary source
information was recorded in that way or because diagnostic
standards were inconsistently applied (Ferlay et al, 2004;
Westlake, 2008, National Cancer Intelligence Network,
2009a,b; Rachet et al, 2009; Sant et al, 2009). This study is
the ﬁrst to use the WHO classiﬁcation (WHO, 2000, 2001,
2008) to examine the age and gender patterns of haematolog-
ical neoplasms in a well deﬁned population, and the beneﬁts of
this are immediately apparent. The analyses revealed that
whilst males are far more likely than females to develop a
haematological neoplasm at any age, there is considerable
variation by subtype (Fig 4), which any aetiological hypothesis
should seek to address. In this regard, exceptions to the
generality of the male excess are also noteworthy – the excess of
women with therapy-related AML, for example, being likely to
reﬂect the use of chemo/radiotherapy in breast cancer (Martin
et al, 2009).
The relationship between age and some lymphoma and
leukaemia subtypes are also well recognized, and descriptive
information is invariably published separately for children and
adults.Thisresultsindataoncancersthatarecomparativelyrare
eitherinchildrenorinadultsoftenbeingoverlooked–attention
being focussed on the age group where the condition is most
common. Our analysis of haematological neoplasms across the
entire age-range conﬁrmed the fact that sporadic cases of
paediatric-type disease can occur in later life, and vice-versa
(Fig 5). This has clear implications not only for aetiological
hypotheses, but also for the delivery of care to patients with
these conditions. Furthermore, the strong age distribution
Table II. Average annual rates (95% conﬁdence intervals) per 100 000 within the HMRN region 2004–2008, and estimated annual numbers for the
UK as a whole*.
Neoplasm
Total Males Females
Rate (95% CI)
Estimated UK
annual cases
Rate
(95% CI)
Estimated UK
annual cases
Rate
(95% CI)
Estimated UK
annual cases
All diagnoses 58Æ5 (57Æ3–59Æ8) 33 376 66Æ3 (64Æ4–68Æ3) 18 602 51Æ2 (49Æ6–52Æ9) 14 774
Chronic myeloid leukaemia 1Æ0( 0 Æ8–1Æ1) 566 1Æ2( 1 Æ0–1Æ5) 350 0Æ7( 0 Æ5–0Æ9) 216
Myeloproliferative neoplasm 5Æ8( 5 Æ4–6Æ2) 3286 4Æ9( 4 Æ4–5Æ5) 1391 6Æ6( 6 Æ0–7Æ2) 1895
Chronic myelomonocytic leukaemia 0Æ5( 0 Æ4–0Æ7) 297 0Æ7( 0 Æ5–0Æ9) 192 0Æ4( 0 Æ3–0Æ6) 105
Myelodysplastic syndromes 3Æ6( 3 Æ3–3Æ9) 2018 5Æ1( 4 Æ6–5Æ7) 1417 2Æ2( 1 Æ8–2Æ5) 602
Acute myeloid leukaemia 4Æ0( 3 Æ7–4Æ3) 2274 4Æ3( 3 Æ8–4Æ8) 1202 3Æ7( 3 Æ3–4Æ2) 1073
Precursor B-lymphoblastic leukaemia 1Æ0( 0 Æ8–1Æ1) 560 1Æ0( 0 Æ8–1Æ3) 291 0Æ9( 0 Æ7–1Æ1) 269
Monoclonal B-cell lymphocytosis 2Æ7( 2 Æ4–3Æ0) 1551 3Æ0( 2 Æ6–3Æ4) 835 2Æ5( 2 Æ1–2Æ8) 716
Chronic lymphocytic leukaemia 5Æ9( 5 Æ5–6Æ3) 3311 7Æ5( 6 Æ9–8Æ2) 2094 4Æ3( 3 Æ8–4Æ8) 1218
Marginal zone lymphoma 2Æ7( 2 Æ5–3Æ0) 1552 3Æ1( 2 Æ7–3Æ5) 858 2Æ4( 2 Æ1–2Æ8) 695
Hairy cell leukaemia 0Æ3( 0 Æ3–0Æ5) 203 0Æ5( 0 Æ4–0Æ7) 154 0Æ2( 0 Æ1–0Æ3) 49
Monoclonal gammopathy of
uncertain signiﬁcance
6Æ2( 5 Æ8–6Æ7) 3544 7Æ3( 6 Æ6–7Æ9) 2023 5Æ3( 4 Æ8–5Æ8) 1521
Plasma cell myeloma 6Æ1( 5 Æ7–6Æ6) 3459 7Æ2( 6 Æ6–7Æ8) 1998 5Æ2( 4 Æ6–5Æ7) 1461
Plasmacytoma 0Æ5( 0 Æ4–0Æ6) 277 0Æ6( 0 Æ5–0Æ9) 180 0Æ3( 0 Æ2–0Æ5) 97
Follicular lymphoma 3Æ1( 2 Æ8–3Æ4) 1800 3Æ0( 2 Æ6–3Æ4) 840 3Æ3( 2 Æ9–3Æ7) 960
Mantle cell lymphoma 0Æ7( 0 Æ6–0Æ9) 395 0Æ9( 0 Æ7–1Æ2) 249 0Æ5( 0 Æ4–0Æ7) 146
Diffuse large B-cell lymphoma 7Æ7( 7 Æ3–8Æ2) 4371 8Æ3( 7 Æ7–9Æ0) 2326 7Æ1( 6 Æ5–7Æ7) 2045
Burkitt lymphoma 0Æ4( 0 Æ3–0Æ5) 222 0Æ6( 0 Æ5–0Æ8) 176 0Æ2( 0 Æ1–0Æ3) 46
Lymphoproliferative disorder NOS  1Æ8( 1 Æ6–2Æ1) 1025 2Æ0( 1 Æ7–2Æ4) 557 1Æ7( 1 Æ4–2Æ0) 468
Precursor T-lymphoblastic leukaemia 0Æ3( 0 Æ2–0Æ4) 173 0Æ4( 0 Æ3–0Æ6) 113 0Æ2( 0 Æ1–0Æ3) 60
T-cell leukaemia 0Æ4( 0 Æ3–0Æ5) 204 0Æ4( 0 Æ2–0Æ5) 100 0Æ4( 0 Æ2–0Æ5) 104
T-cell lymphoma 1Æ1( 0 Æ9–1Æ3) 639 1Æ3( 1 Æ1–1Æ6) 372 0Æ9( 0 Æ7–1Æ2) 267
Lymphocyte predominant
nodular Hodgkin
0Æ3( 0 Æ2–0Æ4) 185 0Æ4( 0 Æ3–0Æ6) 134 0Æ2( 0 Æ1–0Æ3) 50
Classical Hodgkin lymphoma 2Æ5( 2 Æ3–2Æ8) 1463 2Æ7( 2 Æ3–3Æ1) 752 2Æ4( 2 Æ1–2Æ8) 711
*Estimated by applying HMRN sex and age (5-year strata) speciﬁc rates to equivalent UK strata (Census Dissemination Unit & Ofﬁce for National
Statistics, 2009).
 Not otherwise speciﬁed.
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MGUS and their more aggressive counterparts – respectively
CLL and myeloma, provides further evidence that these
conditions are part of a wider continuum (Rawstron et al,
2008; Landgren et al, 2009). Indeed, unlike other cancers,
haematologicalmalignanciesarecharacterizedbytheirabilityto
progress and transform, the longitudinal nature of these
processesbeingcapturedbyHMRNdataacquisitionprocedures.
In this, our ﬁrst report, in-line with current cancer-registration
practice, analyses were based on the number of diagno-
ses (n = 8355) rather than the number of patients (n = 8131).
The proportion of patients with a subsequent diagnosis is
currently small (2Æ8%) – the follow-up period reported on here
being comparatively short and the ﬁndings presented being
unaffected by denominator choice. Future analyses on
individual conditions will factor in this complexity and be
based on the number of patients, rather than their diagnoses.
A key observation within our analyses was that the estimated
UK incidence of haematological neoplasms based on HMRN
rates exceeds national registrations by about 50% (Table II).
Whilst this may be partly due to more complete ascertainment
of certain conditions, there are other contributory factors that
could account for this discrepancy. It has been recognized in
recent years, for example, that occult forms of CLL are not
uncommon in the general population, with reports of up to
12% of adults being affected (Rawstron et al, 2007; Nieto et al,
2009). The term MBL is used when the B-cell count in the
peripheral blood is less than 5 · 10
9/l, and although this
arbitrary cut-off is widely applied, MBL and CLL are part of a
continuum (Rawstron et al, 2008). Hence, the probability that
a patient with MBL or low level CLL will be diagnosed varies
with both local clinical practice and local access to specialist
diagnostic facilities. Many of these patients will neither require
treatment nor have a reduced life expectancy – hence higher
incidence often equates with better survival. Within cancer
registries these patients may not be registered, be registered
inconsistently, or be coded inappropriately. This explains, at
least in part, the large variation in total leukaemia incidence
(A)
(B)
Fig 4. Sex rate ratios: Haematological Malignancy Research Network (HMRN), 2004–2008.
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2001–05 (http://www.ncin.org.uk/eatlas) – the incidence
ranged from 13Æ5 per 100 000 in Yorkshire to 7Æ5 per
100 000 in the adjacent Cancer Network (North of England),
with corresponding 1-year survival estimates of 77Æ6% and
64Æ5%, respectively. This is highly unlikely to reﬂect ‘true’
underlying variation, and almost certainly represents differ-
ences in reporting and ascertainment of the many disease
subtypes that comprise the ‘all leukaemias’ category. Compa-
rable problems exist for MGUS and myeloma, other types of
indolent B-lymphoproliferative disorders, as well as the lower
grade forms of myelodysplasia. In any population within each
of these categories, there will be a pool of undiagnosed
patients, the magnitude of which will vary with local clinical
practice and subsequent data recording.
Whilst individual subtype frequency comparisons between
HMRN and national programmes cannot be made because
their data are not coded to WHO ICD-O-3, it is nonetheless
reassuring to note that HMRN’s rates for clinically evident
disease groupings, such as the Hodgkin lymphomas (Table II),
are very similar to those of NCIN (http://www.ncin.org.uk)
and SEER (http://www.seer.cancer.gov). However, even in
patients with clinically acute disease, where overall levels of
ascertainment are more standard, there are several issues that
must be considered before valid comparisons of clinical
outcome are made between treatment centres. In this regard,
a further crucial step in interpreting ﬁndings is the incorpo-
ration of molecular markers. The WHO classiﬁcation (WHO,
2008), for example, recognizes a number of speciﬁc AML
subtypes based on cytogenetic and molecular abnormalities,
each of which has well deﬁned clinical characteristics and
outcomes (Weltermann et al, 2004; Gale et al, 2008; Rau &
Brown, 2009) – the survival plots presented in Fig 6 clearly
show the importance of taking such markers into account.
Patients with more advanced CLL provide another example
where outcome and survival vary with prognostic factors such
as TP53 inactivation and immunoglobulin mutation status
(Vasconcelos et al, 2003; Byrd et al, 2006; Dicker et al, 2009).
Obviously, making comparisons between centres and individ-
uals in the absence of data on prognostic factors could lead to
erroneous conclusions being drawn. This not only has
implications for local governance and research, but also for
the growing number of commercial health care information
providers who routinely tabulate data and rank centres.
(A)
(B)
Fig 5. Age at diagnosis distributions: Haematological Malignancy Research Network (HMRN), 2004–2008.
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clinical trial, in particular the emphasis on primary source
measurements, is integral to HMRN data collection proce-
dures. For example, for diffuse large B-cell lymphoma,
follicular lymphoma and Hodgkin lymphoma, international
prognostic scoring systems are widely used to stratify patients
in clinical trials (Hasenclever & Diehl, 1998; Buske et al, 2006;
Sehn et al, 2007) – it is, however, well recognized that such
indices are not routinely recorded for non-trial patients. As
illustrated in Fig 7, HMRN actively addresses this through the
collection of component data from multiple primary sources,
using disease-speciﬁc abstraction forms that enable embedded
algorithms to accurately calculate stage and prognostic score.
In the future, these data will provide the contextual framework
for evaluating clinical outcomes and assessing the generaliz-
ability of clinical trial ﬁndings to the wider patient population.
This is a much needed requirement in the UK because, whilst
haemato-oncology has been cited as a specialty with a strong
commitment to clinical trials and evidence based therapy
(National Cancer Research Network, 2009a,b), it is also
recognized that, overall, as few as 5% of patients are treated
in the context of a clinical trial (National Institute for Clinical
Excellence, 2003). In fact, population-based ﬁgures on trial
participation are rarely available for haematological malignan-
cies, either as a whole or by subtype, largely because the totality
of the patient population within the relevant disease subtype
groupings is unknown – this is true both in the UK and
elsewhere in the world. Indeed, whether or not a patient is
entered into a clinical trial is affected by many factors, and the
data presented here conﬁrm that this process is far from
random (National Institute for Clinical Excellence, 2003;
Department of Health, 2007). This lack of representativeness
has clear implications for the external validity of trial ﬁndings,
as well as for the common tendency to extrapolate trial data for
commissioning purposes (National Institute for Clinical
Excellence, 2003; Murthy et al, 2004; Cronin et al, 2005;
Vickers, 2008; Estey, 2009; Friedberg et al, 2009).
How patients are treated obviously affects outcome, and
here again data for haematological malignancies are particu-
larly variable and complex, as is illustrated in Fig 8, which
shows two examples of HMRN myeloma patient pathways.
This intricacy is captured within HMRN by abstracting
complete treatment histories, which is essential because,
although primary treatment is usually standardized, this is
not so for relapsed patients who may require salvage
therapy(s). In this case potential treatment options and the
allocation to a particular treatment course increasingly depend
on physician and patient choice – as well as national and local
funding policies (Department of Health, 2007, 2008). A similar
situation exists for more indolent conditions, such as CLL and
follicular lymphoma, where the decision to initiate treatment
and subsequent treatment options may vary with both
individual patient and/or clinician choice, as well as with
treatment centre. Importantly, in addition to facilitating
analyses that will enable therapeutic decisions to be based on
evidence of efﬁcacy. The collection of entire treatment histories
also reveals pathways that are amenable to comparative
economic analysis. This will become increasingly relevant as
many patients with haematological malignancies who would
once have died from their disease fairly rapidly, now survive.
However, unlike survivors from other forms of cancer they
often require life-long treatment(s) – either continuously or
episodically. This has major, but poorly deﬁned implications
for the health economy and as such will be a key area for future
HMRN analyses aimed at informing the process of commis-
sioning cancer services.
This review of the ﬁrst 4 years of HMRN demonstrate that
within the framework of the UK National Health Service
(NHS), it is feasible to collect data to the standard required,
both to inform patient care and to provide the foundation for
current and future research. HMRN was initiated to serve both
research and clinical needs, and as such the capture of all
patients diagnosed and treated is a paramount objective.
Accurately characterizing the case-mix, as we have been able to
do, is critical for interpreting incidence patterns and for
(A)
(B)
Fig 6. Kaplan–Meier survival estimates for (A) AML patients by ICD-
O-3 subtype and (B) for AML not otherwise speciﬁed (NOS) patients
according to FLT3 length mutation status: Haematological Malignancy
Research Network (HMRN), 2004–2008.
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outcome, but at present, relevant data of this type are rarely
systematically collected (Sehn et al, 2005). HMRN is based in
two Cancer Networks, and as such reﬂects the infrastructure of
national cancer care delivery in the UK where patients are
diagnosed and treated locally (National Institute for Clinical
Excellence, 2003; National Cancer Intelligence Network,
2009a). The age and sex structure of the population of
3Æ6 million mirrors that of the UK as a whole, and there is no
reason to believe that the population-based ﬁndings are not
generalizable to the country as a whole. Furthermore, in
contrast to many other cancers there is little evidence to
suggest that haematological disease varies systematically with
factors such as social class (Smith et al, 2006; National Cancer
Intelligence Network, 2009c), although broad variations with
ethnicity have been reported (National Cancer Intelligence
Network, 2009d). Issues such as these will be investigated in
detail in future reports.
Haematological oncology is changing rapidly, with new
approaches to treatment and diagnosis continually emerging as
diverse patient pathways evolve. There are now examples
where the use of reﬁned diagnostic techniques and classiﬁca-
tions is beginning to uncover underlying genetic factors in the
pathogenesis of haematological neoplasms (Jones et al, 2009;
Kilpivaara et al, 2009). For example, gene expression proﬁling
and other techniques are now demonstrating the linkage
between disease categories, such as mediastinal B-cell lym-
phoma and classical Hodgkin lymphoma (Rosenwald et al,
2003; Savage et al, 2003), while subdividing others, such as
diffuse large B-cell lymphoma, in ways that may reﬂect
underlying pathogenesis (Wright et al, 2003; Lossos et al, 2004;
Tome et al, 2005; Malumbres et al, 2008; Alizadeh et al, 2009).
Importantly, HMRN combines the necessary high quality
population-based data collection systems and diagnostic
facilities to further investigate the epidemiology of these
emerging entities.
Fig 7. International Prognostic Index (IPI) derivation from components in diffuse large-B-cell lymphoma (DLBCL): Haematological Malignancy
Research Network (HMRN), 2004–2008. (ECOG, Eastern Cooperative Oncology Group).
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to collect haematological malignancy data to the standard
required to inform patient care and provide a solid
foundation for research using the framework of the UK
National Health Service (NHS). Indeed, HMRN’s maturing
data presents an increasingly valuable resource to address
real questions of concern to haematologists, commissioners,
health service researchers and patients. However, the
wide-ranging challenges of acquiring sufﬁciently detailed
information mean that this model would be extremely
difﬁcult to replicate across the UK as a whole. Accordingly,
a sample method based on stable populations such as
Table III. First-line trial recruitment distributed by age and diagnosis: Haematological Malignancy Research Network (HMRN), 2004–2008.
Overall
Age (years)
0–14 15–29 30–44 45–59 60–74 75+
All Diagnoses Total 8355 158 242 451 1380 3098 3026
Trial (%) 7Æ25 9 Æ52 4 Æ01 4 Æ29 Æ66 Æ41 Æ9
Precursor B-lymphoblastic leukaemia Total 137 73 15 17 13 14 5
Trial (%) 68Æ68 9 Æ08 6 Æ75 2 Æ94 6 Æ27 Æ10
Precursor T-lymphoblastic leukaemia Total 43 18 13 3 2 3 4
Trial (%) 55Æ88 3 Æ36 1 Æ50 5 0 Æ00 0
Acute myeloid leukaemia Total 570 18 37 53 89 169 204
Trial (%) 34Æ46 1 Æ17 3 Æ06 4 Æ25 5 Æ13 4 Æ97 Æ8
Plasma cell myeloma Total 876 – – 14 144 352 366
Trial (%) 13Æ7– –3 5 Æ72 1 Æ51 6 Æ57 Æ1
Chronic myeloid leukaemia Total 137 – 8 19 46 42 22
Trial (%) 11Æ0– 01 3 Æ31 7 Æ41 1 Æ90
Mantle cell lymphoma Total 100 – – – 11 42 47
Trial (%) 8Æ0– – – 1 8 Æ21 1 Æ92 Æ1
Burkitt lymphoma Total 54 15 6 5 10 12 6
Trial (%) 7Æ403 3 Æ32 0 0 0 1 6 Æ7
Classical Hodgkin lymphoma Total 360 16 98 76 53 70 47
Trial (%) 5Æ80 7 Æ15 Æ37 Æ65 Æ74 Æ3
Diffuse large B-cell lymphoma Total 1098 9 19 67 206 416 381
Trial (%) 4Æ51 1 Æ15 Æ34 Æ58 Æ75 Æ50 Æ8
Other haematological malignancies Total 4980 9 46 197 806 1978 1944
Trial (%) 1Æ52 2 Æ2– 3 Æ11 Æ62 Æ20 Æ5
Fig 8. Myeloma patient pathway of two patients: Haematological Malignancy Research Network (HMRN), 2004–2008.
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to the current information strategy for haematological
cancers.
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Patmore, Mike Richards, Hazeem Sayala, Geoff Sherton,
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Emma Thomas, Adrian Williams, Andrzej Wieczorek, David
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Haematological malignancy diagnostic service
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Helen Dickinson, Paul Evans, Andrew Jack, Richard Jones,
Sheila O’Connor, Roger Owen, Andy Rawstron, Steve Rich-
ards, David Swirsky, Reuben Tooze, Lisa Worrillow.
Epidemiology and genetics unit
Pat Ansell, John Blase, Ian Cope, Helen Cox, Simon Crouch,
Will Curson, James Doughty, Jan Farish, Susanne Grifﬁths,
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